GlycoMimetics Begins Phase 1 Trial Of GMI-1271 For Blood-Related Cancers

(RTTNews) - GlycoMimetics, Inc. (GLYC) Thursday said it has begun its Phase 1 clinical trial for evaluating the safety, tolerability and pharmacokinetics of GMI-1271, a drug candidate, for treating acute myeloid leukemia.

This was following pre-clinical studies of GMI-1271, which made the company believe that, this drug candidate has the potential to be an important new therapy for people with certain blood cancers as well as for those with high risk of metastasis in certain solid tumors.

The single-site Phase 1 trial of GMI-1271, is a randomized, double-blind, placebo-controlled, single ascending intravenous dose study, assessing GMI-1271 in 28 healthy adult subjects. The company expects to publish the final data in the second half of 2014.

GlycoMimetics's next planned study is a Phase 1/2 trial of GMI-1271 as an adjunct to standard chemotherapy in patients with AML.